Entrectinib

361 interactions 392 cited references

Also sold as: Rozlytrek Rozlytrek®

About Entrectinib

Entrectinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. It is also used to treat certain types of solid tumors in adults and children 12 years of age and older that cannot be treated by surgery or that has spread to other parts of the body… Read the full Entrectinib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Rubella Virus Vaccine, Live Piperaquine Posaconazole Saquinavir Ketoconazole Topical Pimozide

29 Contraindicated 325 Major 7 Moderate

All (361) Contraindicated (29) Major (325) Moderate (7)

Major

Entrectinib Mizolastine An increased risk of QT interval prolongation Details Entrectinib Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure; QT interval prolongation Details Entrectinib Modafinil Provigil Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Moricizine An increased risk of QT interval prolongation Details Entrectinib Morphine Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Entrectinib Morphine Sulfate Liposome Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Entrectinib Moxifloxacin Avelox An increased risk of QT interval prolongation Details Entrectinib Nafarelin An increased risk of QT interval prolongation Details Entrectinib Nafcillin Reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Nefazodone Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Nelfinavir Viracept Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Entrectinib Netupitant Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Nifedipine Adalat® Increased NIFEdipine exposure Details Entrectinib Nilotinib Increased entrectinib exposure, an increased frequency or severity of adverse reactions including increased risk of cardiac arrhyt... Details Entrectinib Nirogacestat Ogsiveo Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse effects Details Entrectinib Norfloxacin An increased risk of QT interval prolongation Details Entrectinib Octreotide Bynfezia An increased risk of QT interval prolongation Details Entrectinib Ofloxacin Floxin® An increased risk of QT interval prolongation Details Entrectinib Olanzapine An increased risk of QT interval prolongation Details Entrectinib Olodaterol Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Entrectinib Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Entrectinib Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Entrectinib Ondansetron An increased risk of QT interval prolongation Details Entrectinib Osilodrostat Isturisa Increased risk of QT interval prolongation Details Entrectinib Osimertinib Tagrisso An increased risk of QT interval prolongation Details Entrectinib Oxaliplatin Increased risk of QT-interval prolongation Details Entrectinib Ozanimod Additive effects on heart rate Details Entrectinib Pacritinib Vonjo® Reduced CYP3A4 substrate with NTI exposure, reduced efficacy of CYP3A4 substrate with NTI and an increased risk of QT interval pro... Details Entrectinib Palbociclib Ibrance Increased exposure to CYP3A substrates with a narrow therapeutic index Details Entrectinib Paliperidone Erzofri An increased risk of QT interval prolongation Details Entrectinib Panobinostat Farydak An increased risk of QT interval prolongation Details Entrectinib Papaverine Pavacot® An increased risk of QT interval prolongation Details Entrectinib Paritaprevir Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Entrectinib Paroxetine Paxil An increased risk of QT interval prolongation Details Entrectinib Pasireotide Signifor An increased risk of QT interval prolongation Details Entrectinib Pazopanib Votrient An increased risk of QT interval prolongation Details Entrectinib Pentamidine NebuPent An increased risk of QT interval prolongation Details Entrectinib Perphenazine An increased risk of QT interval prolongation Details Entrectinib Phenobarbital Fidoquel An increased risk of QT interval prolongation, reduced entrectinib exposure and reduced efficacy of entrectinib Details Entrectinib Phenytoin Dilantin Reduced entrectinib exposure and reduced efficacy of entrectinib Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.